Document Detail

Current role of pharmacogenomics in cardiovascular medicine.
MedLine Citation:
PMID:  21537956     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Pharmacogenomics holds the promise of transforming patient care by allowing providers to tailor therapy to each individual patient based on his or her genetic information. Although no established pharmacogenomic applications in cardiovascular medicine yet exist, there are at least three emerging applications that may ultimately become routine clinical practice; these are related to warfarin, clopidogrel, and statins. Of the three, warfarin pharmacogenomics has been the most rigorously evaluated to date, with several clinical trials either completed or underway. Clopidogrel pharmacogenomics has a growing body of supporting scientific evidence and warrants evaluation in prospective clinical trials. Statin pharmacogenomics remains the least developed application, with controversy surrounding a widely marketed genetic test whose validity has been questioned by recent evidence. Providers are advised to take a "wait and see" approach to pharmacogenomics at the present time, with the expectation that it will be a few years before any cardiovascular pharmacogenomic application is unequivocally proven to be both cost-effective as well as of clinical benefit.
Kiran Musunuru
Related Documents :
15462666 - Staying human in the medical family: the unique role of doctor-parents.
19641086 - Utilization of western medicine and traditional chinese medicine services by physicians...
17367526 - Does a self-referral counselling program reach doctors in need of help? a comparison wi...
21261216 - The process of producing a "nice" guideline.
21564426 - Communities of practice: the missing link for knowledge management on implementation is...
8727166 - Complementary medicine use in a dementia clinic population.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in cardiovascular medicine     Volume:  13     ISSN:  1534-3189     ISO Abbreviation:  Curr Treat Options Cardiovasc Med     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-11     Completed Date:  2011-07-14     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815942     Medline TA:  Curr Treat Options Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  302-12     Citation Subset:  -    
Center for Human Genetic Research, Cardiovascular Research Center, Massachusetts General Hospital, 185 Cambridge St CPZN 5th floor, Boston, MA, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The in vitro MN assay in 2011: origin and fate, biological significance, protocols, high throughput ...
Next Document:  Molecular dynamics simulation and density functional theory studies on the active pocket for the bin...